DECISION WILL HELP PROTECT SENIORS, TAXPAYERS AND THE U.S. HEALTH SYSTEM FROM EGREGIOUS PRICING ON AN UNPROVEN TREATMENT
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in reaction to a proposed National Coverage Determination decision for monoclonal antibodies for the treatment of Alzheimer’s from the Centers for Medicare & Medicaid Services (CMS). The proposed decision would govern Medicare coverage for the controversial and unproven brand name treatment Aduhelm.
“CSRxP commends CMS officials for recognizing the need for more data on Aduhelm’s clinical value for patients before extending full coverage for an unproven treatment with an egregious price tag,” said CSRxP executive director Lauren Aronson. “CMS’ balanced approach rightfully focuses on ensuring covered medications deliver better health outcomes for patients. The proposed policy will help protect seniors, taxpayers and the U.S. health care system from shouldering undue costs from the outrageous Big Pharma pricing of this medication.”
“Seniors who rely on Medicare Part B to cover their outpatient care faced a historic increase to their health care premiums as a result of Big Pharma’s pricing of this unproven treatment. CSRxP encourages CMS to revisit and reduce that increase in light of the proposed coverage policy,” Aronson added. “CSRxP also looks forward to working with policymakers and regulators at all levels of government to ensure future policy decisions reflect careful consideration of a medication’s clinical value for patients balanced with its likely cost to patients and the health care system.”
Read more about the Big Pharma pricing of Aduhelm HERE.
Learn more about solutions to hold Big Pharma accountable and lower prescription drug prices HERE.